320 likes | 739 Views
History of Fibrosing Alveolitis. Corrigan 1838: ?on cirrhosis of the lung"Hamman-Rich syndrome 1935Scadding 1964 ? Fibrosing alveolitisIdiopathic pulmonary fibrosis in USAAverrill Liebow ? pathology 1950s. Associations of ILD. Inorganic dusts (pneumoconiosis)Organic dusts (Hypersensitivity Pn
E N D
1. Interstitial Lung Disease-associations with autoantibodies Dr Felix Woodhead
Locum Respiratory Physician UHCW
5 October 2010
2. History of Fibrosing Alveolitis Corrigan 1838: “on cirrhosis of the lung”
Hamman-Rich syndrome 1935
Scadding 1964 – Fibrosing alveolitis
Idiopathic pulmonary fibrosis in USA
Averrill Liebow – pathology 1950s
3. Associations of ILD Inorganic dusts (pneumoconiosis)
Organic dusts (Hypersensitivity Pneumonitis)
Drugs
Rheumatological disease
Idiopathic
4. Cryptogenic Fibrosing Alveolitis Bibasal Crackles
Restrictive Spirometry or isolated low TLco
Basally-predominant fibrosis on CXR
Absence of pneumoconiosis, EAA or known connective tissue disease
RA, SLE
SSc, PM/DM SSc is an uncommon CTD with a prevalence about 50 times less than RA
Skin fibrosis is the hallmark but internal organ involvement is also common
However distinct organs are involved in a particular patient
Common sites of damage include the pulmonary interstitium (causing fibrosis) and the pulmonary vasculature as well as the kidneys and GI tract
Often difficult to disentangle particularly breathlessness may be caused by pulmonary fibrosis or vasculature and sensitive markers such as DLCO may be affected by both
Would be useful to distinguish who is at risk perhaps when treatment may be more effective
One way is extent of cutaneous disease. Skin thickening proximal to the elbows defined as diffuse cutaneous rather than lcSSc.
Pts with dcSSc more likely to have PF and renal crisis, lcSSc PAH but can get PF with lcSSc tooSSc is an uncommon CTD with a prevalence about 50 times less than RA
Skin fibrosis is the hallmark but internal organ involvement is also common
However distinct organs are involved in a particular patient
Common sites of damage include the pulmonary interstitium (causing fibrosis) and the pulmonary vasculature as well as the kidneys and GI tract
Often difficult to disentangle particularly breathlessness may be caused by pulmonary fibrosis or vasculature and sensitive markers such as DLCO may be affected by both
Would be useful to distinguish who is at risk perhaps when treatment may be more effective
One way is extent of cutaneous disease. Skin thickening proximal to the elbows defined as diffuse cutaneous rather than lcSSc.
Pts with dcSSc more likely to have PF and renal crisis, lcSSc PAH but can get PF with lcSSc too
5. Patient 1
6. Patient 1 – Histopathology UIP
7. Patient 1 –Idiopathic Pulmonary Fibrosis (IPF) Not interchangeable term for Idiopathic Interstitial Pneumonia
?most common IIP
Relatively poor prognosis
Median survival 2 ˝ years
Histology
Usual Interstitial Pneumonitis (UIP) when biopsied
Temporal and Spatial heterogeneity, not uniform
Radiology
Typical features: basal, peripheral honeycombing, little ground glass
May have any appearance
Typical features – don’t need to biopsy, atypical – biopsy helpful
8. Patient 2
9. Patient 1
10. Patient 2 – Respiratory Bronchiolitis
11. Smoking-related IIP Respiratory Bronchiolitis
Histological appearance in ‘healthy smokers’
Pigmented macrophages in terminal bronchioles
Clinical condition RB associated ILD (RBILD)
RBILD radiology similar to Hypersensitivity Pneumonitis (EAA)
BAL not lymphocytic
DIP
‘Desquamative’ due to erroneous belief cells shed into alveoli
Diffuse collection of pigmented macrophages throughout alveoli
Radiologically typified by diffuse GGO
?smoking related NSIP, Fibrosis and emphysema
12. The _IPs: Interstitial Pneumonias UIP – Usual, the most common, IPF
NSIP – non-specific
AIP – acute, Hamman-Rich, ARDS
DIP – desquamative, ?macrophages, smoking (RBILD – respiratory bronchiolitis – associated ILD)
LIP – lymphocytic, HIV and connective tissue disease
13. 2002 ATS/ERS guidelines for Idiopathic Interstitial Pneumonia
14. Patient 3
15. Cryptogenic Fibrosing Alveolitis Bibasal Crackles
Restrictive Spirometry or isolated low TLco
Basally-predominant fibrosis on CXR
Absence of pneumoconiosis, EAA or known connective tissue disease
RA, SLE
SSc, PM/DM SSc is an uncommon CTD with a prevalence about 50 times less than RA
Skin fibrosis is the hallmark but internal organ involvement is also common
However distinct organs are involved in a particular patient
Common sites of damage include the pulmonary interstitium (causing fibrosis) and the pulmonary vasculature as well as the kidneys and GI tract
Often difficult to disentangle particularly breathlessness may be caused by pulmonary fibrosis or vasculature and sensitive markers such as DLCO may be affected by both
Would be useful to distinguish who is at risk perhaps when treatment may be more effective
One way is extent of cutaneous disease. Skin thickening proximal to the elbows defined as diffuse cutaneous rather than lcSSc.
Pts with dcSSc more likely to have PF and renal crisis, lcSSc PAH but can get PF with lcSSc tooSSc is an uncommon CTD with a prevalence about 50 times less than RA
Skin fibrosis is the hallmark but internal organ involvement is also common
However distinct organs are involved in a particular patient
Common sites of damage include the pulmonary interstitium (causing fibrosis) and the pulmonary vasculature as well as the kidneys and GI tract
Often difficult to disentangle particularly breathlessness may be caused by pulmonary fibrosis or vasculature and sensitive markers such as DLCO may be affected by both
Would be useful to distinguish who is at risk perhaps when treatment may be more effective
One way is extent of cutaneous disease. Skin thickening proximal to the elbows defined as diffuse cutaneous rather than lcSSc.
Pts with dcSSc more likely to have PF and renal crisis, lcSSc PAH but can get PF with lcSSc too
16. Systemic Sclerosis Scleroderma – skin thickening above MCPs
Sclerodactyly – skin thickening of fingers
Digital pitting scars
Bibasal pulmonary fibrosis
Major criterion or two or more minor criteria
Limited cutaneous (lcSSc) vs diffuse cutaneous (dcSSc)
lcSSc ‘CREST’ syndrome
17. Interstitial Pneumonia in Systemic Sclerosis >50% patients ?(TLco) in early studies
Manoussakis et al. Chest 1987
Steen et al. Arthritis Rheum 1985
Since Rx for renal crisis, lung disease leading cause of death
Ferri et al Medicine (Baltimore) 2002
Scussel-Lonzetti et al Medicine (Baltimore) 2002
Simeon et al Rheumatology.(Oxford) 2003
More common in dcSSc
FA-SSc thought to be indistinguishable from CFA
Harrison et al. Am Rev Resp Dis 1991
SSc ILD has a better prognosis than CFA
Wells et al. AJRCCM 1994
19. Autoantibodies – Antinuclear Antibodies Using Indirect Immunofluorescence on human cell lines, ANA are found in up to 95% of cases of SSc
As early as 1980 it was realised that some patterns had clinical associations with the centromere pattern highly associated with the CREST syndrome which is now recognised as a form of lcSSc
Other common patterns are of homogeneous nuclear staining and a nucleolar pattern.
Despite the patterns it is not always possible to determine the underlying antigen
Using Indirect Immunofluorescence on human cell lines, ANA are found in up to 95% of cases of SSc
As early as 1980 it was realised that some patterns had clinical associations with the centromere pattern highly associated with the CREST syndrome which is now recognised as a form of lcSSc
Other common patterns are of homogeneous nuclear staining and a nucleolar pattern.
Despite the patterns it is not always possible to determine the underlying antigen
20. Anticentromere Antibodies Associated with CREST
Tan et al Arthritis Rheum 1980
Riboldi et al Clinical and Experimental Rheumatology 1985
Less likely than ACA neg to have pulmonary fibrosis
Steen et al Arthritis Rheum 1988
Kane et al Respiratory Medicine 1996
Defined by IIF pattern
Antigen not soluble
6 defined antigens
ELISA available but not widely used
21. Anti-topoisomerase 1 antibodies 2/3 ATA dcSSc
Steen et al Arthritis Rheum 1988
Associated with pulmonary fibrosis
Cassani et al Clin Exp Rheumatol 1987
Manoussakis et al Chest 1987
Steen et al Arthritis Rheum 1988
22. Antibody characterisation IIF pattern Anticentromere (ACA)
ENA Anti-topoisomerase 1(ATA)
Double immunodiffusion (Ouchterlony)
Counterimmunoelectrophoresis (CIE)
ELISA Anti-RNA polymerase I&III (ARA)
Immunoblot
Radiolabelled protein / RNA immunoprecipitation Th/To,others
24. Radiolabelled protein immunoprecipitation patterns
25. RNA immunoprecipitation
26. Autoantibodies in Systemic Sclerosis Anti-centromere: lcSSc and pulmonary hypertension
Anti-topoisomerase 1: dcSSc and interstitial pneumonia
Anti-RNA polymerase I & III: dcSSc, renal crisis, ‘watermelon stomach’
Anti-PMScl: scleroderma/polymyositis overlap
Th/To: ‘scleroderma sine scleroderma’
Anti-U3 RNP: dcSSc, African American ethnicity
Other SSc-associated AAs: U1-RNP, Ro, La etc
27. Polymyositis/Dermatomyositis Symmetrical proximal muscle weakness
Elevated serum muscle enzymes
EMG changes
Abnormal muscle biopsy
± skin rash (Heliotrope rash, Gottron rash)
4 criteria ‘definite’, 3 ‘probable’, 2 ‘possible’
28. Autoantibodies in Idiopathic Inflammatory Myopathies – PM/DM Jo-1: histidyl tRNA synthetase
6 other tRNA synthetase antibodies
Anti-synthetase syndrome 20% IIM
High incidence interstitial pneumonia,
Arthritis, Raynaud’s, ‘mechanic’s hands’
Mi-2: 5% IIM, predominantly DM, negative assoc IP
Anti-Signal recognition particle: bad myopathy
‘Clinically amyopathic dermatomyositis’- CADM
30. Are Autoantibodies useful in Idiopathic Disease? Useful in phenotyping connective tissue disease
ANAs occur in 37% ‘CFA’ (Turner-Warwick)
22% my studied patients
CTD – associated AAs found in IPF cohorts
CTD-like symptoms common in idiopathic patients, biopsies NSIP > UIP
31. Is it important? CTD-associated ILD has better outcome
Immunosuppressants
?Lesson from rheumatologists about ‘early synovitis’
32. Coventry and Warwickshire ILD service Established by David Parr/Christine O’Brien
Monthly multidisciplinary meeting
Thoracic surgeon present
Future developments
Bronchoalveolar lavage
Antinuclear antibody testing
Research/Trials
Specialist nurse
33. Questions?